Louisiana 2022 Regular Session

Louisiana Senate Bill SB388

Introduced
3/4/22  
Introduced
3/4/22  
Refer
3/4/22  
Refer
3/4/22  
Refer
3/14/22  
Report Pass
4/12/22  
Report Pass
4/12/22  
Engrossed
4/26/22  
Engrossed
4/26/22  
Refer
4/27/22  
Refer
4/27/22  
Report Pass
5/17/22  
Report Pass
5/17/22  
Enrolled
6/5/22  
Enrolled
6/5/22  
Chaptered
6/17/22  
Chaptered
6/17/22  
Passed
6/17/22  

Caption

Prohibits the sale of certain abortion-inducing drugs without a prescription and provides for criminal penalties. (8/1/22) (EN INCREASE GF EX See Note)

Impact

The bill significantly impacts state laws concerning the regulation of abortion-inducing drugs, effectively making it illegal to sell or distribute these drugs via mail or online. Criminal penalties outlined include fines up to $50,000 and imprisonment for up to ten years for violations that result in harm. It also includes provisions specifying that actions taken by licensed healthcare providers for bona fide medical needs will not incur penalties, provided they are appropriately documented. This addition is aimed at safeguarding healthcare providers who operate within the law while ensuring compliance with the new regulations.

Summary

Senate Bill No. 388 aims to regulate the sale and dispensation of abortion-inducing drugs in the state of Louisiana. The bill prohibits the prescription, dispensing, and distribution of such drugs without the physical presence of a prescribing physician. Moreover, it defines 'criminal abortion' in the context of these drugs, outlining specific criminal penalties for violations. The legislation is framed as a means to ensure that abortions are conducted safely, and that women receiving such care do so under appropriate medical supervision.

Sentiment

The sentiment around SB388 is highly polarized. Supporters, primarily from conservative factions, argue that the bill enhances the control over abortion practices in hopes of protecting unborn lives and the health of women. They view it as a necessary measure in light of recent shifts in federal abortion policy. Conversely, opponents, including various women's rights groups and some healthcare advocates, argue that the bill undermines women's autonomy and access to healthcare options. They express concerns that it could lead to further restrict women's choices and limit their rights to safe and legal medical procedures.

Contention

Notable points of contention include the operating definitions within the bill regarding what constitutes an abortion-inducing drug, the role of healthcare providers, and the implications for women's rights. Critics argue that the bill's requirement for physical presence during the administration of these drugs may create barriers for women seeking abortions, particularly in rural areas where physicians are scarce. Furthermore, the concern about criminal penalties for healthcare professionals acting in good faith reflects a broader debate about the implications of state control over medical practices and individual rights.

Companion Bills

No companion bills found.

Similar Bills

LA HB526

Prohibits the imposition of prior authorization requirements in Medicaid managed care organizations for certain prescription medications used in treating opioid use disorder (RE DECREASE SG RV See Note)

LA SB496

Provides for limits on certain medical prescriptions. (8/1/14)

LA SB371

Provides relative to opioid prescriptions. (gov sig)

LA SB143

Enacts Alison Neustrom Act and provides relative to prescribed marijuana for therapeutic uses and the development of rules and regulations by the Louisiana Board of Pharmacy and the Louisiana State Board of Medical Examiners. (gov sig)

LA SR211

Requests the Louisiana Department of Health to implement a policy prohibiting excessive Medicaid reauthorizations for patients using life-sustaining devices.

LA HB319

Provides relative to the dispensing of interchangeable biological products

LA SCR26

Provides relative to legislative intent of certain Acts relating to causes of action for abuse of a minor.

LA SB41

Provides relative to the regulation of pharmacy benefit managers. (See Act) (EN INCREASE SG EX See Note)